Financings in Brief: Aksys, Ltd
This article was originally published in The Gray Sheet
Executive Summary
Aksys, Ltd: Adopts shareholder rights plan intended to protect shareholders in the event of of a takeover attempt. Under the plan, shareholders of record on Nov. 8 receive one preferred share purchase right for every common stock share held. The rights become exercisable "if a person acquires, or announces a tender offer for, 15% or more of the company's common stock," Aksys says. The development stage hemodialysis product firm netted $52.2 mil. from its May 16 initial public offering of 3.6 mil. shares at $16 each ("The Gray Sheet" June 3, p. 12)...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.